Navigation Links
Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
Date:9/5/2007

Lung Cancer

SCLC is the most aggressive and deadly form of lung cancer and accounts for approximately 20 percent of all lung cancer cases. The current two-year survival rate for patients with extensive SCLC is less than 10 percent with current management options. The estimated incidence of lung cancer in the United States in 2006 was 174,500, according to the National Cancer Institute. The estimated incidence in Europe in 2006 was 386,300, according to the International Agency for Research on Cancer.

SCLC is currently treated with platinum therapies, but many patients do not respond, and if they do respond, they typically relapse within a short time after treatment. There is currently no FDA-approved therapy and no consistent and effective therapy for SCLC patients who have platinum-resistant or -refractory disease after treatment failure with first-line combination therapy with either cisplatin or carboplatin. No new drugs have been approved by the FDA for the treatment of platinum-resistant or -refractory SCLC in nearly a decade.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead product candidate, is a new generation platinum therapy with an improved safety profile. Picoplatin is designed to overcome and prevent platinum resistance associated with chemotherapy in solid tumors. Intravenous picoplatin is currently being studied in clinical trials for the treatment of small cell lung, colorectal and hormone-refractory prostate cancer, and oral picoplatin is in a clinical trial in solid tumors. As part of the Company's strategic goal of building a diverse oncology pipeline, the Company is collaborating with The Scripps Research Institute on the discovery of novel, small-molecule, multi-targeted protein kinase inhibitors. For additional infor
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
2. Poniard Pharmaceuticals Announces Clinical Data from Picoplatin Phase 2 Small Cell Lung Cancer Trial To Be Presented at American Society of Clinical Oncology Annual Meeting
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... 16 Optimer Pharmaceuticals, Inc. (Nasdaq: ... 28th Annual J.P. Morgan Healthcare Conference at the ... Wednesday, January 13, 2010. Michael N. Chang, Optimer,s ... 2:30 p.m. Pacific Time (5:30 p.m. Eastern Time). ... audio webcast of this presentation will be accessible ...
(Date:12/16/2009)... 16 , ... Microplasmin Recruits a Total of Over,640 patients ... ThromboGenics NV (Euronext Brussels: THR), a ... of innovative treatments for eye,disease, vascular disease ... completed,the enrolment of the second Phase III ...
(Date:12/15/2009)... Inc., a global leader focused on improving blood collection, ... to provide blood centers with Alyx® system supplies needed ... filed yesterday against Fenwal by Haemonetics Corporation ( HAE). ... an advanced medical instrument used worldwide to collect two ... about 30 minutes. ,, Fenwal will ask ...
Breaking Medicine Technology:Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference 2ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 2ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 3ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 4Fenwal Responds to New Lawsuit From Haemonetics; Reiterates Commitment to Blood Centers 2Fenwal Responds to New Lawsuit From Haemonetics; Reiterates Commitment to Blood Centers 3Ethiopias climate 27 million years ago had higher rainfall warmer soil 10491 1Ethiopias climate 27 million years ago had higher rainfall warmer soil 10491 2Syphilis survey reveals need for accurate testing for early infection 59960 1RIT scientist shines laser light on methane in pursuit of clean fuel 10490 1RIT scientist shines laser light on methane in pursuit of clean fuel 10490 2
... Computerized tomographic (CT),colonography, also known as virtual colonoscopy, ... flexible tube with a camera to view the,lining ... detect cancer and,precancerous polyps and could serve as ... the results of the American College of,Radiology Imaging ...
... Biotech has become,aware of preliminary data from an ... in patients with acute ischemic stroke. In,this study, ... with,Epoetin alfa within six hours of the onset ... placebo. Ortho Biotech has reported this,information to the ...
Other Medicine Technology:Video: Large, Multi-Center Trial Demonstrates Comparable Accuracy for Virtual Colonoscopy and Standard Colonoscopy 2Video: Large, Multi-Center Trial Demonstrates Comparable Accuracy for Virtual Colonoscopy and Standard Colonoscopy 3Video: Large, Multi-Center Trial Demonstrates Comparable Accuracy for Virtual Colonoscopy and Standard Colonoscopy 4
(Date:12/16/2009)... through national AAD program ,, SCHAUMBURG, ... from melanoma, the deadliest form of skin cancer, ... treated, if caught early. That,s why thousands of ... screenings in their communities through the American Academy ... The program recently reached a milestone - two ...
(Date:12/16/2009)... -- For ages, people from around the world have ... soothing waters have a reputation that dates back over ... miracles. Now, with the introduction of two bath salt ... the legendary benefits of Dead Sea salt in their ... all-natural Dead Sea salt and essential oils - but ...
(Date:12/16/2009)... International, Inc. (OTC Bulletin Board: MZEI) ... Board of Medizone New Zealand Ltd., a joint ... 50% interest, agreed on December 14, 2009 to ... International all global marketing rights of the company,s ... Marshall said, "Time has eroded the relevance of ...
(Date:12/16/2009)... While many of the,pharma companies are struggling ... and inmarket drugs, MarketsandMarkets on the other ... players. These pharma,forecasting solutions are designed for ... phase,III. These have a substantial impact on ... strategy, manufacturing planning, sales force,promotion, and planning. ...
(Date:12/16/2009)... could improve care, but privacy a concern, doctors ... U.S. physicians support the use of electronic medical ... two new studies show. , One study of ... in Massachusetts found that 86 percent believed electronic ... of care, 70 percent thought it would reduce ...
Breaking Medicine News(10 mins):Health News:Dermatologists Reach Skin Cancer Screening Milestone 2Health News:Dermatologists Reach Skin Cancer Screening Milestone 3Health News:SaltWorks Launches Two All-Natural Bath Salt Lines Featuring Therapeutic Salt from the Dead Sea 2Health News:SaltWorks Launches Two All-Natural Bath Salt Lines Featuring Therapeutic Salt from the Dead Sea 3Health News:Medizone International, Inc. Approves Repurchase of Global Marketing Rights 2Health News:MarketsandMarket's Integrated Patient-based Forecasting Solution for Pharmaceutical Industry, Mainly for Pipeline Products 2Health News:MarketsandMarket's Integrated Patient-based Forecasting Solution for Pharmaceutical Industry, Mainly for Pipeline Products 3Health News:Pros and Cons of Electronic Medical Records Weighed 2
... (NEWARK, N.J., Oct. 3,2007) Rutgers College of Nursing faculty ... of the Nurse Educator of the New York Times 2007 ... three practicing nurses and one nurse educator from hundreds of ... The winners will be featured in a special section in ...
... , WEDNESDAY, Oct. 3 (HealthDay News) -- Identifying a ... best chemotherapy for patients, U.S. research suggests. , "We ... likely to respond to standard first-line therapy and which ... second-line therapy, based on gene expression profiling," lead author ...
... The screen uses CT scans and is performed without ... new study supports the effectiveness of an innovative form ... sent through a patient,s colon. , When it ... so-called "virtual colonoscopy" is just as effective as the ...
... WEDNESDAY, Oct. 3 (HealthDay News) -- Drug-coated stents offered ... patients with blocked coronary arteries, a large Canadian study ... artery become blocked again after stent implant -- was ... getting drug-coated stents, 7.4 percent versus 10.7 percent. The ...
... WHNN radio personality,Bob Hughes, a well-known voice in the Saginaw ... is moving to Saginaw this,month. "My hearing became damaged ... the quality of my life has changed significantly since being,fitted ... Hearing,",says Hughes. "I am really enjoying my new ears." ...
... UNION CITY, Calif., Oct. 3 Abaxis, Inc.,(Nasdaq: ... point-of-care,blood chemistry analysis systems, announced today the launch ... conjunction with the Piccolo xpress(TM) point of,care analyzer. ... specifically for imaging and,radiology centers in the United ...
Other Medicine News:Health News:Rutgers College of Nursing faculty member Rachel Jones wins New York Times Nurse Award 2Health News:Gene Tests Match Up Lung Tumors, Best Treatment 2Health News:'Virtual' Colonoscopy an Effective Option: Study 2Health News:'Virtual' Colonoscopy an Effective Option: Study 3Health News:Study Finds Benefits With Drug-Coated Stents 2Health News:Study Finds Benefits With Drug-Coated Stents 3Health News:WHNN's Bob Hughes Fitted With Hearing Aids by Mobile Care Hearing Clinic Now Serving Saginaw Area 2Health News:Abaxis Announces New Waived Kidney Check Panel Exclusively for Imaging and Radiology Centers 2Health News:Abaxis Announces New Waived Kidney Check Panel Exclusively for Imaging and Radiology Centers 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: